Sc‐RNAseq studies by Tuveson's group characterised iCAFs and myCAFs, and identified a novel class of MHC class II and CD74 expressing ‘antigen presenting’ CAFs in KPC mouse and human tumours; KPC‐derived apCAFs were able to activate CD4+ T‐cells in an antigen‐specific manner, in keeping with a role in tumour immune surveillance, at least in the KPC murine model [66]. The gene discussed is CD74; the disease is neoplasm.